Flag of the European Union EU Clinical Trials Register Help

Clinical trials for lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,347 result(s) found for: lymphoma. Displaying page 40 of 68.
    «« First « Previous 36  37  38  39  40  41  42  43  44  Next» Last»»
    EudraCT Number: 2020-001856-16 Sponsor Protocol Number: 35RC17_9804_REVOLUMHOD Start Date*: 2020-09-08
    Sponsor Name:Rennes University Hospital
    Full Title: Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumor VOLUME in Patients Treated for Conventional HODgkin's Lymphoma
    Medical condition: Refractory Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005702-22 Sponsor Protocol Number: IELSG39 Start Date*: 2013-03-17
    Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP
    Full Title: International prospective Phase 2 trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycycline followed by eradication moni...
    Medical condition: Patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000097-56 Sponsor Protocol Number: HOVON110 Start Date*: 2013-06-11
    Sponsor Name:HOVON Foundation
    Full Title: ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma A HOVON/GLSG/NCRI study
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016905 Follicle centre lymphoma, follicular grade I, II, III recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-004493-96 Sponsor Protocol Number: CT-P10-3.3 Start Date*: 2014-03-21
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Phase 1/3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, E...
    Medical condition: Advanced Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016910 Follicle centre lymphoma, follicular grade I, II, III stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016909 Follicle centre lymphoma, follicular grade I, II, III stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) GR (Completed) IT (Completed) PT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-002302-30 Sponsor Protocol Number: 83/2004/U/Sper Start Date*: 2004-07-20
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: FMZ Fludarabine, Mitoxantrone, Zevalin regimen a phase II study as front-line treatment in indolent non-follicular non-Hodgkins lymphoma patients
    Medical condition: Confirmed histologic diagnosis according to the REAL classification of B-cell indolent lymphoma including small lymphocytic, immunocytoma, and marginal zone lymphoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10003900 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004377-84 Sponsor Protocol Number: GO27834 Start Date*: 2013-04-11
    Sponsor Name:Genentech, Inc.
    Full Title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980S) in combination with rituximab or polatuzumab vedotin (DCDS4501A) in combi...
    Medical condition: Follicular Non-Hodgkin’s Lymphoma (FL); Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    20.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    20.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    20.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-001052-39 Sponsor Protocol Number: DSHNHL2006-1A Start Date*: 2010-04-14
    Sponsor Name:University Medicine Goettingen
    Full Title: Auto-versus Allotransplantation in T-NHL - Autologous or allogeneic transplantation following conventional chemotherapy in younger patients (18-60 yrs.) with mature (peripheral) T-cell lymphoma
    Medical condition: Peripheral (mature) T-cell lymphoma, first diagnosis, ALK-negative
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006028-41 Sponsor Protocol Number: BER-PUM-01 Start Date*: 2022-02-21
    Sponsor Name:Pomorski Uniwersytet Medyczny w Szczecinie
    Full Title: Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN
    Medical condition: Primary central nervous system lymphoma (PCNSL) and secondary non-Hodgkin's lymphoma with central nervous system involvement (NHL-CNSI)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000704-28 Sponsor Protocol Number: GCP#05.01.020 Start Date*: 2016-06-16
    Sponsor Name:Gamida Cell Ltd
    Full Title: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord...
    Medical condition: High risk haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    19.0 100000004864 10009015 Chronic myeloid leukemia LLT
    19.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002261-22 Sponsor Protocol Number: KTE-C19-107 Start Date*: 2018-09-11
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
    Medical condition: Relapsed/Refractory Diffuse Large B cell Lymphoma (r/r DLBCL).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) BE (Completed) IT (Completed) ES (Ongoing) FR (Completed) SE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000087-29 Sponsor Protocol Number: MO28543 Start Date*: 2013-08-26
    Sponsor Name:F. Hoffmann- La Roche Ltd.
    Full Title: A multicenter, open-label, single-arm, phase IIIb, international study evaluating the safety of Obinutuzumab alone or in combination with chemotherapy in patients with previously untreated or relap...
    Medical condition: Chronic lymphocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    16.0 100000004864 10008977 Chronic lymphocytic leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) ES (Completed) FI (Completed) LV (Completed) SI (Completed) IE (Completed) PT (Completed) EE (Completed) GR (Completed) SE (Completed) PL (Completed) SK (Completed) BE (Completed) LT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005843-40 Sponsor Protocol Number: PXD101-CLN-19 Start Date*: 2008-11-11
    Sponsor Name:Spectrum Pharmaceuticals Inc.
    Full Title: A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Medical condition: Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) ES (Completed) HU (Completed) SK (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003931-40 Sponsor Protocol Number: BRD/05/95 Start Date*: 2006-04-20
    Sponsor Name:University College London
    Full Title: Phase ll Trial of Fludarabine & Cyclophosphamide followed by Thalidomide for Angioimmunoblastic Lymphoma
    Medical condition: Angioimmunoblastic T-cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002197-34 Sponsor Protocol Number: 04/Q1104/27 Start Date*: 2004-12-14
    Sponsor Name:University College London
    Full Title: A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed d...
    Medical condition: Newly diagnosed diffuse large B cell non-Hodgkin's lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-003077-25 Sponsor Protocol Number: VELCADE-MALT- LYMPHOM Start Date*: 2005-09-13
    Sponsor Name:AKH Vienna
    Full Title: PHASE II TRIAL OF BORTEZOMIB (VELCADE®) IN PATIENTS WITH ADVANCED OR RELAPSED LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT)
    Medical condition: patients with MALT-lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002103-32 Sponsor Protocol Number: 50-03B Start Date*: 2005-03-02
    Sponsor Name:GELA-Recherche Clinique
    Full Title: Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma,...
    Medical condition: CD 20 positive diffuse large B cell lymphoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005515-51 Sponsor Protocol Number: 202000814 Start Date*: 2021-06-28
    Sponsor Name:Medical University Medical Center Groningen
    Full Title: An explorative and feasibility study of Venetoclax combined with Tamoxifen in patients with relapsed/refractory Diffuse Large B-cell Lymphoma
    Medical condition: relapsed/refractory Diffuse Large B-cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005015-16 Sponsor Protocol Number: BBBD-01 Start Date*: 2017-01-24
    Sponsor Name:Oulu University Hospital
    Full Title: Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous system lymphoma
    Medical condition: Primary centra nervous system lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006030-40 Sponsor Protocol Number: Pola_R Start Date*: 2022-05-31
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
    Full Title: EFFICACY OF POLATUZUMAB, BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MANTLE CELL LYMPHOMA – A SINGLE CENTER PHASE II TRIAL
    Medical condition: MANTLE CELL LYMPHOMA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000719-17 Sponsor Protocol Number: PIVeR Start Date*: 2018-03-05
    Sponsor Name:LYSARC
    Full Title: A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etop...
    Medical condition: Patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10029608 Non-Hodgkin's lymphomas unspecified histology aggressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 36  37  38  39  40  41  42  43  44  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Feb 13 22:55:39 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA